Prometheus | Mamacrowd

TAX Bonus

Innov SME


Bioindustry Park
B Heroes


Medical Devices

Medtech startup developing devices for regenerative medicine. The flagship product is Ematik: a personalized patch that halves wound healing time, without scarring.

  • € 20 billion market, 25% growth for advanced products

  • Veterinary market validated product with proven efficacy

  • Comprehensive and competent team with excellent Advisors

  • Reliability of EU validated plan and patents filed

Professional Investor

Professional Inv.

Goal min 350 k€

OVERFUNDING New goal max: 1 Mln€

Total Collected

1,0 Mln€




7,2 Mln€

Minimum goal

350 k€

Minimum Order

499,8 €



  • Abstract Operation
  • Product
  • Customer Need
  • Technology
  • Market and Target
  • Customer and Traction
  • Marketing & Sales
  • Business Model
  • Competitors
  • Financial projections
  • Use of funds
  • Team
immagine copertina

Abstract Operation

Prometheus is aninnovative medtech startup founded in 2017, which creates solutions for regenerative medicine and aims to integrate advanced technologies in the treatment of difficult-toheal skin wounds, such as pressure sores and diabetic ulcers.

From Prometheus comes Ematik: a personalised, bioresorbable plaster that combines the patient's blood with special biomaterials for the treatment of difficult wounds. The patch halves wound healing time by stimulating regeneration, without scar formation.


20 Million patients have a chronic wound, and every 30 seconds a limb is amputated due to lack of products that stimulate fast and effective regeneration. This forces patients to undergo frequent and painful treatments, which are often inconclusive. The products available today are ineffective.
The market for wound care products is worth €20 billion, with an annual growth rate of advanced products of 25%, indicating that advanced therapies will increasingly replace the use of traditional products.

Ematik has alreadydemonstrated its effectiveness on numerous animal clinical cases, in fact, it is already on the veterinary market since February 2020 for the treatment of wounds in dogs, cats and horses. The technology is also covered by 3 patents, which will be extended worldwide.

The team is extremely motivated, supported by an advisory board of excellence that includes Dr. Andrea Chies i of Chiesi farmaceutici (2nd most important Italian multinational pharmaceutical company); his value has also been recognized by the Seal of Excellence of the European Commission.
From a clinical point of view, the project is also supported by wound care luminaries, such as Dr. Lorenz Larcher of the Sant'Anna Clinic in Merano and Dr. Longobardi of the Hyperbaric Institute in Ravenna.


Thanks to your contribution, it will be possible to certify Ematik for human use and start today the regenerative medicine of the future.


On the campaign of Prometheus Srl is mandatory the Massive Rubrication Service for all membership amounts lower than 29.995,14€. The service is offered at no additional cost to the investor.


Want to find out more about this project?

Do you already have an account?


The information on the offer is not subject to approval by Consob. The Offering company is solely responsible for the completeness and truthfulness of the data and information provided by the latter. The investor's attention is also drawn to the fact that the investment, even indirect, through OICR or companies that invest mainly in financial instruments issued by innovative startups and SMEs is illiquid and characterised by a very high risk.

Warnings pursuant to Article 19(2)
crowdfunding services provided by Mamacrowd are not covered by the Deposit Guarantee Scheme established in accordance with Directive 2014/49/EU*; securities and instruments eligible for crowdfunding purposes that can be acquired through this crowdfunding platform are not covered by the Investor Compensation Scheme established in accordance with Directive 97/9/EC**.
* Directive 2014/49/EU of the European Parliament and of the Council on Deposit Guarantee Schemes.
** Directive 97/9/EC of the European Parliament and of the Council on investor-compensation schemes.


© 2023 SiamoSoci Srl a company of Azimut Group - VAT number IT07464370969 - Via Timavo 34, 20124 MI - SC € 95.417,54 fully paid up - Registr. 8, resolution 19002 of 06/08/14

By using the services of Mamacrowd you accept our cookies policy. We and our partners operate globally and use cookies, including for statistical, advertising and customisation purposes.

Show preferences